Selectivity in glycosaminoglycan binding dictates the distribution and diffusion of fibroblast growth factors in the pericellular matrix by Sun, Changye et al.
 on March 23, 2016http://rsob.royalsocietypublishing.org/Downloaded from rsob.royalsocietypublishing.orgResearch
Cite this article: Sun C, Marcello M, Li Y,
Mason D, Le´vy R, Fernig DG. 2016 Selectivity
in glycosaminoglycan binding dictates the
distribution and diffusion of fibroblast growth
factors in the pericellular matrix. Open Biol. 6:
150277.
http://dx.doi.org/10.1098/rsob.150277Received: 23 December 2015
Accepted: 2 March 2016Subject Area:
biochemistry/cellular biology
Keywords:
glycosaminoglycan, heparan sulfate, fibroblast
growth factor, extracellular matrix,
growth factor diffusionAuthor for correspondence:
David G. Fernig
e-mail: dgfernig@liverpool.ac.ukElectronic supplementary material is available
at http://dx.doi.org/10.1098/rsob.150277.& 2016 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original
author and source are credited.Selectivity in glycosaminoglycan binding
dictates the distribution and diffusion
of fibroblast growth factors in the
pericellular matrix
Changye Sun1, Marco Marcello2, Yong Li1, David Mason2, Raphae¨l Le´vy1
and David G. Fernig1
1Department of Biochemistry, Institute of Integrative Biology, and 2Centre for Cell Imaging, Institute of
Integrative Biology, University of Liverpool, Liverpool L69 7ZB, UK
CS, 0000-0001-8602-9629; YL, 0000-0002-5594-4434; DM, 0000-0002-8773-5274;
RL, 0000-0001-5728-0531; DGF, 0000-0003-4875-4293
The range of biological outcomes generated by many signalling proteins in
development and homeostasis is increased by their interactions with glycosami-
noglycans, particularly heparan sulfate (HS). This interaction controls the
localization andmovement of these signalling proteins, butwhether such control
depends on the specificity of the interactions is not known. We used five fibro-
blast growth factors with an N-terminal HaloTag (Halo-FGFs) for fluorescent
labelling, with well-characterized and distinct HS-binding properties, and
measured their binding and diffusion in pericellular matrix of fixed rat mam-
mary 27 fibroblasts. Halo-FGF1, Halo-FGF2 and Halo-FGF6 bound to HS,
whereas Halo-FGF10 also interacted with chondroitin sulfate/dermatan sulfate,
and FGF20 did not bind detectably. The distribution of bound FGFs in the peri-
cellular matrix was not homogeneous, and for FGF10 exhibited striking clusters.
Fluorescence recovery after photobleaching showed that FGF2 and FGF6
diffused faster, whereas FGF1 diffused more slowly, and FGF10 was immobile.
The results demonstrate that the specificity of the interactions of proteins
with glycosaminoglycans controls their binding and diffusion. Moreover, cells
regulate the spatial distribution of different protein-binding sites in glycosamino-
glycans independently of each other, implying that the extracellular matrix has
long-range structure.
1. Background
The extracellular matrix has a central role in mediating communication between
animal cells through mechanisms mediated by mechanical forces and soluble
effectors. A large proportion of the soluble effectors, morphogens, growth factors,
cytokines and chemokines that regulate animal development and homeostasis
interact with glycosaminoglycans, particularly heparan sulfate (HS), of the extra-
cellular matrix [1,2]. These interactions have been shown to exhibit varying
degrees of specificity and selectivity at the tissue and at the molecular
levels, and in a number of cases have been demonstrated to control the effectors’
transport and intracellular signalling.
TheglycosaminoglycansHS, chondroitin sulfateanddermatansulfate are linear,
sulfated polysaccharides covalently attached to core proteins to formproteoglycans.
Theseareeitherassociatedwith thecellmembraneandresident inpericellularmatrix
or secreted, so resident in extracellularmatrix.The longchainsofHS (approx. 25–100
disaccharide units) consist of repeats of a disaccharide: D-glucosamine b 1–4
glucuronic acid or its epimer iduronic acid. The mature chains have a distinct
domain structure of sequential blocks of unmodified disaccharides of N-acetyl
glucosamine b 1–4 glucuronic acid, transition domains where N-acetyl glucosa-
mine-containing disaccharides alternate with N-sulfated ones, and sulfated
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O-sulfated on C3 and C6, and the uronic acid is often epimerized
to iduronate, which may be 2-O-sulfated [1–3].
At least 435 extracellular regulatory proteins bind to tran-
sition and S-domains [4] (reviewed in [1,2]). At the molecular
level, analysis of the structural basis of the interaction of individ-
ual proteins with HS andmodel polysaccharides (derivatives of
the related heparin) shows that there is a selectivity by proteins
for particular patterns of sulfation [5–7].At the tissue level, clear
differences in the expression of sulfated sugar structures have
been demonstrated, which impact on cell communication in
development, homeostasis and disease [8–13].
One important functional consequence of proteins binding
HS is its potential to control the movement of effectors between
cells. Endothelial cell extracellular matrix, in the 1980s, was
demonstrated to be capable of storing fibroblast growth factor
(FGF) 2, which could then transfer to its cellular receptors to
stimulate the cells [14]. Later, HS in extracellular matrix was
shown to control the diffusion of FGF2 [15], which indicated
that HS had the potential to shape FGF2 gradients (FGF2
being both a growth factor and a morphogen [16]). Sub-
sequently, the binding of a number of morphogens to HS
was shown to control their diffusion in contexts ranging from
Drosophila to vertebrates [17–22]. However, this may not be
universal [23–25]. Moreover, it is not clear whether it is
the selectivity of an effector for particular structures in the
polysaccharide or just non-selective ion-exchange protein–
polysaccharide interactions [26] that are important in regulating
the effector’s diffusion. A related issue is that HS in extracellular
matrix has been viewed as homogeneous, that is, there is no
variation in the distribution of binding sites below the scale
of tissue compartments. However, work with nanoparticle-
labelled FGF2 demonstrated that the distribution of its binding
sites in fibroblast pericellular matrix is heterogeneous and clus-
tered from length scales of approximately 20 nm to 1 mm and
above [27]. Recently, biophysical experiments have shown that
some effectors that bindHS can cross-link the chains of the poly-
saccharide [28]. This suggests that HS chains in extracellular
matrix may be organized into supramolecular structures,
which could impose selectivity on protein-binding that is of
higher spatial order than possible with individual chains.
To test these ideas, we have used five FGFs (FGF1, 2, 6, 10
and 20) with distinct HS-binding sites and binding selectivity
for structures in the polysaccharide [29,30]. These FGFs were
expressed as N-terminal HaloTag fusions (Halo-FGFs) [31],
which permitted specific fluorescent labelling. Measurement
of the binding and diffusion of the Halo-FGFs to glycosami-
noglycans in the pericellular matrix of fibroblasts revealed
that there were very substantial differences between these
FGFs in their level of binding, their spatial distribution and
their diffusion. These data indicate that HS chains in pericel-
lular matrix are organized over length scales far greater than
that of a single chain, and that this serves to present distinct
numbers and spatial patterns of binding sites for effectors,
which in turn modulates the diffusion of the proteins.2. Material and methods
2.1. Protein production
The FGFs and Halo-FGFs were produced exactly as described
in detail previously [29,31]. HaloTag protein was producedby digestion of Halo-FGF20 with TEV protease and purified
by anion-exchange on DEAE Sepharose Fast Flow (GE
Healthcare, Buckinghamshire, UK). Protein concentrations
were determined by measuring their absorbance at 280 nm
using a NanoDrop 1000 spectrophotometer (Thermo Scientific,
Leicestershire, UK).
2.2. Protein labelling
HaloTag and Halo-FGFs (0.5 mM) were incubated with
2.5 mM HaloTag TMR ligand (Promega UK Ltd, Hampshire,
UK) in 100 ml phosphate-buffered saline (PBS: 2.7 mM KCl,
10 mM Na2HPO4, 1.8 mM KH2PO4 and 0.15 M NaCl,
pH 7.4) at room temperature for 30 min, then kept on ice
before use the same day. To determine the extent of labelling,
TMR-dye-labelled Halo-FGFs were loaded onto a mini
heparin agarose (BioRad, Hertfordshire, UK) column (20 ml)
and washed with PBS containing 0.05% (v/v) Tween-20.
The bound TMR-labelled Halo-FGFs were eluted with
2 M NaCl buffered with phosphate (PB: 2.7 mM KCl,
10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4). The quantum
yields were measured in a fluorescence spectrophotometer
(Varian, Walton-on-Thames, UK) by excitation at 561 nm
and emission from 565 to 700 nm.
2.3. Cell culture
Rat mammary (Rama) 27 fibroblasts were cultured with
Dulbecco’s modified Eagle’s medium (Life Technologies,
Paisley, UK) supplemented with 10% (v/v) fetal calf
serum (Labtech International Ltd, East Sussex, UK), 4 mM
L-glutamine (Life Technologies), 0.75% sodium bicarbonate
(Life Technologies), 50 ng ml21 insulin (Sigma-Aldrich,
Dorset, UK) and 50 ng ml21 hydrocortisone (Sigma-Aldrich),
as described previously [32].
2.4. Cell labelling
Rama 27 cells were cultured on glass bottomed imaging
dishes (CELLview Culture dish: 35 mm non-treated glass
bottom, Greiner Bio-one, Stonehouse, UK) and fixed with
4% (w/v) paraformaldehyde dissolved in PBS. The fixed
cells were washed with PBS three times and then incubated
with 2 ml PBS containing 10 mg ml21 BSA to block any
remaining partially active fixative. The blocking medium
was discarded after 15 min, and the fixed cells were incu-
bated with 1.5 ml 10 nM TMR dye, 2 nM TMR-labelled
HaloTag or 2 nM TMR-labelled Halo-FGFs for 30 min at
378C. The excess TMR dye and TMR dye-labelled Halo-
FGFs (TMR-Halo-FGFs) were removed by three washes
with PBS. In competition experiments, the competitor was
added along with the labelled Halo-FGF at concentrations
indicated in the figure legends. Degradation of HS was
achieved in fixed Rama 27 cells by incubation with 1 ml
heparinase I, II and III (50 mU ml21 each in 100 mM
sodium acetate and 0.1 mM calcium acetate, pH 7.0; gift
from Prof. Jerry Turnbull, University of Liverpool). Chon-
droitin sulfate (including dermatan sulfate) was degraded
by incubation with 1 ml chondroitinase ABC (Sigma-Aldrich;
400 mU ml21 in PBS). In both cases, cells were incubated
with the enzymes overnight at 378C prior to incubation
with Halo-FGFs.
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A LSM780 confocal microscope with an environmental con-
trol chamber (Zeiss, Jena, Germany) was used to acquire
cell imaging data with a DPSS 561 nm excitation laser. For
all cell imaging, a 63X oil immersion lens (Plan-Apochromat
63 1.4 oil DIC M27) and a 15.03 Airy Units pinhole were
used. Cell images (67.3 mm  67.3 mm, 512  512 pixels,
16 bits) containing bright field and the red fluorescence
channels were collected for the binding assays. Images were
collected using identical microscope settings.
2.6. Fluorescence recovery after photobleaching
The fixed cells labelled with TMR-Halo-FGF1 (2 nM and
1 nM), TMR-Halo-FGF2 (2 nM), TMR-Halo-FGF6 (2 nM)
and TMR-Halo-FGF10 (2 nM) were used for the FRAP exper-
iments. The measurements were performed at 378C. A square
area (22.49  22.49 mm, 256  256 pixels, eight bits) was
imaged six times with the 63X oil immersion lens, and then
the selected 2.5 mm (radius) disc area was bleached with the
561 nm laser at full power for eight iterations (0.64 s in total).
After that, another 195.6 s of images (994 images) were
acquired to measure the fluorescence recovery. An area free
of cells and a non-bleached area on the same cell were selected
to determine the background (subtracted in quantifications)
and correct the photobleaching caused by the excitation laser
during imaging, respectively. The fluorescence intensities of
these three selected areas from 0 to 197.2 s were extracted
using ZEN 2012 software (Zeiss) for further analysis.2.7. Data analysis
Fluorescence intensity of the labelled cells: the cell edgeswere auto-
matically identified by using publishedMatlab codes [33], and
the fluorescence intensities were averaged for each cell. The cell
edges of low fluorescence-labelled cells were detected in the
bright field channel image (electronic supplementary material,
figures) and high fluorescence-labelled cells were detected in
the fluorescence channel image. The Matlab program for cell
edge detection can be downloaded from GitHub (https://
github.com/hscsun/DrawCellEdges.git).
FRAP data analysis: the background fluorescence intensity
(Ib) was subtracted from both the bleached area (I ) and
non-bleached reference area (Ir). The photobleaching was cor-
rected by the reference area and Ic is the corrected
fluorescence intensity of the bleaching area.
Ic ¼ (I  Ib) Ir[1 6] IbIr  Ib
 
: ð2:1Þ
Note: Ir[1–6] means the averaged fluorescence intensity of the
reference area of the first six images; the other fluorescence
intensities (I, Ib, Ic, Icn and Idcn) are applied to any image in
the frame, but they correspond to the same image number
in both sides of the equation for each calculation (from
frame 1 to 1000 in this FRAP experiment).
The fluorescence intensity of the bleaching area was nor-
malized to the averaged fluorescence intensity of the first six
images, where Icn is the corrected and normalized intensity of
the image.
Icn ¼ IcIc[1 6] : ð2:2ÞNote: Ic[1–6] means the average of the first six corrected
fluorescence intensities from equation (2.1).
To compare fluorescence recovery curves, the corrected
and normalized fluorescence intensity of the first bleached
image, Icn[7], was subtracted from the corrected fluorescence
intensity of bleached area and the FRAP curve was
normalized again, as in equation (2.2).
Idcn ¼ Icn  Icn[7]1 Icn[7] : ð2:3Þ
Note: here [7] means the seventh image (or the first
image after bleaching) for the normalized and corrected
fluorescence intensity.
The final recovery level (If ), the fluorescence intensity for
the last measurement and half recovery time (t1/2) were
extracted from the corrected and normalized curve acquired
from equation (2.3) by
If ¼ Idcnðt ¼ finalÞ ð2:4Þ
and
t1=2 ¼ ta þ tb2 : ð2:5Þ
Note: tmeans time; final is the time at which the last imagewas
acquired in the actual experiments. ta is the time corresponding
to the maximum value of the fluorescence intensities smaller
than half of If; tbis the time corresponding to the minimum
value of the fluorescence intensities larger than half of If.
The radial profiles of the bleaching area were extracted
using a published Matlab code [34], and the photobleaching
was corrected for each analysed image as described in
equation (2.1). The Matlab program for FRAP data analysis
can be downloaded from GitHub (https://github.com/
hscsun/ImagingDataAnalyzerForFRAP.git).
All calculations and image montages were done with
Matlab R2014a.
Boxplots of the half recovery time and final recovery level
of different Halo-FGFs were prepared in ORIGINPRO v. 9. The
data plot with standard deviation area was prepared using a
published Matlab code [35].3. Results and discussion
3.1. Labelling Halo-FGFs with TMR-Halo
ligand dye
The N-terminal HaloTag fusion does not affect the binding of
FGFs to heparin or their biological activity and they are effi-
ciently expressed [31]. So, they provide a convenient means to
prepare genetically encoded fluorescently labelled FGFs,
whose excitation and emission properties can be altered by
changing the HaloTag ligand [36]. We first tested whether
the HaloTag TMR ligand dye interacted with heparin or
grossly affected the interaction of the FGFs with heparin.
A mixture of HaloTag and a fivefold excess of Halo-TMR
dye was incubated for 30 min and loaded onto a mini heparin
column. After three 50 ml washes with PBS containing 0.05%
(v/v) Tween-20 (PBST) to remove the unbound dye, there
was no red fluorescence detectable on the heparin column
(figure 1a). This indicated that neither HaloTag nor the
TMR-Halo ligand dye bound to heparin. In contrast, the
heparin column loaded with TMR-labelled Halo-FGF2 gave
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Figure 1. Conjugation and quantification of TMR dye-labelled Halo-FGFs. Halo-TMR dye was used to label HaloTag and Halo-FGFs at a ratio of 5 : 1 (mole/mole).
The labelled HaloTag and Halo-FGFs were loaded onto a mini heparin column, which was subsequently washed with PBST. (a) The HaloTag and Halo-FGF2-loaded
heparin columns were visualized under a red fluorescence filter (ImageQuant LAS 4000 imager, GE Healthcare). (b) The five TMR-labelled Halo-FGFs were loaded
onto mini heparin-affinity chromatography columns, washed with PBS buffer and eluted with 2 M NaCl in the same buffer. The fluorescence intensities of the five
purified Halo-FGFs were quantified in a fluorimeter by measuring the emission from 565 to 700 nm excited with 561 nm.
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Halo-FGF2 was labelled with TMR-Halo ligand dye and
retained its heparin-binding properties. Following purifi-
cation of fluorescent-dye-labelled Halo-FGFs on mini
heparin columns, the bound TMR-Halo-FGFs were eluted
with 2 M NaCl. The fluorescence emission curves of the pur-
ified Halo-FGFs demonstrated that the emission peak of TMR
dye remained at 580 nm and that the emission curves of these
Halo-FGFs were quite similar (figure 1b). Although there was
a small difference of the fluorescence intensity for each TMR-
Halo ligand labelled Halo-FGF, especially for Halo-FGF20,
the results indicate that the labelling of different Halo-FGFs
was very consistent and efficient.3.2. Binding of different Halo-FGFs to Rama 27
fibroblast pericellular matrix heparan sulfate
Rama 27 fibroblasts were fixed with paraformaldehyde with-
out permeabilization prior to imaging, so only extracellular
binding sites will be measured [27]. This will also stop cellu-
lar biochemical processes, so binding of FGFs to pericellular
matrix will not be affected by internalization.3.2.1. Halo-FGF2
The fixed Rama 27 fibroblasts were incubatedwith 2 nMHalo-
FGFs to determine if their binding capacities to HS in the peri-
cellular matrix of these cells differed. Halo-FGF2 strongly
bound to Rama 27 fibroblasts (figure 2a). The bright spots
show the heterogeneities in the distribution of the Halo-FGF2
(figure 2a, arrows).
To detect the autofluorescence from the imaged cells and
the interactions of HaloTag with this pericellular matrix, a
number of controls were used. The BSA-blocked cell dish
was visualized by confocal microscopy. The cell edges were
detected by the bright field image (electronic supplementary
material, figure S1b), and no autofluorescence from the cellswas observed in the fluorescence channel image (figure 2b).
Using the same microscope settings, when TMR-Halo ligand
alone and TMR-Halo ligand-labelled HaloTag were incubated
with the fixed Rama 27 cells, the fluorescence was the same as
observed with a BSA-blocked culture dish with cells; no red
fluorescence was detectable (figure 2c,d ). When the fixed
cells were incubated with 2 nM TMR-labelled Halo-FGF2 and
with either of two unlabelled competitors, 8 mM unlabelled
FGF2 or Halo-FGF2, the binding was reduced to undetectable
levels (figure 2e,f ). These data indicate that non-specific bind-
ing of TMR-Halo ligand and of TMR-Halo ligand-labelled
HaloTag protein was within the levels of background fluor-
escence and that the fluorescence observed with labelled
Halo-FGF2 in Rama 27 pericellular matrix (figure 2a) was
entirely owing to the FGF2 moiety of the Halo-FGF2.
To determinewhat Halo-FGF2was binding to in the pericel-
lular matrix of Rama 27 fibroblasts, a series of competition and
enzyme digestion experiments were performed, again using
the same microscope settings. Competition with heparin
(4 mg ml21 added with Halo-FGF2) abolished binding, and flu-
orescence was reduced to background levels (figure 2g). This
indicates that FGF2 is probably bound to glycosaminoglycans
of the pericellular matrix. Moreover, while heparin will effec-
tively compete for binding of FGF2 to glycosaminoglycans, it
still enables FGF2 to bind to the FGFR on these cells [37]. There-
fore, Rama 27 fibroblasts were subjected to heparinase and
chondroitinaseABCdigestion to ascertain its bindingpartner(s).
Incubation of fixedRama27 fibroblastswithheparinases I, II and
III prior to the addition of Halo-FGF2 reduced the level of fluor-
escence to background levels (figure 2h). In contrast,
chondroitinase ABC digestion of the cells did not appreciably
alter the binding of TMR-Halo-FGF2 to Rama 27 cell
(figure 2i). These data demonstrate that TMR-Halo-FGF2 is pri-
marily bound to HS in the pericellular matrix of Rama 27
fibroblasts. Moreover, these results are consistent with previous
data, which indicate that more than 99% of binding sites for
FGF2 on Rama 27 fibroblasts are HS, and the FGFR less than
1% [27,38].
(b) (c)
(h)(g) (i)
(d ) (e) ( f )
(a)
Figure 2. Halo-FGF2 binding to Rama 27 fibroblasts. The binding specificity of Halo-FGF2 to Rama 27 cells was determined by competing with unlabelled FGFs and
heparin, and by digestion with heparinases and chondroitinase ABC. TMR-Halo-FGF2 (2 nM), Halo-TMR dye or TMR-HaloTag were used to label fixed Rama 27
fibroblasts for 30 min. The excess Halo-FGF2, Halo-TMR dye or TMR-HaloTag was removed by washing with PBS three times. The cell edges are highlighted
with white lines. (a) TMR-Halo-FGF2 (2 nM). (b) Unlabelled cells imaged to show the autofluorescence. (c) Halo-TMR dyes (2 nM) to measure the non-specific
binding of ligand dye to cells or glass dish. (d ) TMR-HaloTag (2 nM) to determine the level of binding of HaloTag. (e,f ) Cells incubated with 2 nM
TMR-Halo-FGF2 and (e) 8 mM unlabelled Halo-FGF2 or ( f ) 8 mM FGF2. (g) 2 nM TMR-Halo-FGF2 and 4 mg ml21 heparin. (h) Cells were incubated with hepar-
inases I, II and III to remove heparan sulfate and then incubated with 2 nM TMR-Halo-FGF2. (i) Cells were incubated with chondroitinase ABC to digest chondroitin
sulfate and then incubated with 2 nM TMR-Halo-FGF2. The corresponding bright field images are presented in electronic supplementary material, figure S1. Size of
the scale bar is 20 mm.
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The binding of TMR-labelled Halo-FGF1 to Rama 27 cells was
somewhat stronger than that observed for Halo-FGF2
(figures 2a and 3a). Because the labelling efficiencies of the
Halo-FGFs are similar, this indicates that FGF1 at this concen-
tration possesses more binding sites on these cells than FGF2.
As for Halo-FGF2, the distribution of the fluorescence was not
homogeneous (figure 3a). The lower fluorescence intensity in
the centre of the cell was the result of the high focal plane of
the plasma membrane in this region owing to the underlying
cell nucleus. The same competition and enzyme digestion
experiments performed with Halo-FGF2 were done with
Halo-FGF1, to identify its binding partner(s) inRama27pericel-
lular matrix. Both unlabelled 8 mM Halo-FGF1 and FGF1
effectively competed with 2 nM TMR-Halo-FGF1 (figure 3b,c).
Addition of 4 mg ml21 heparinwith TMR-Halo-FGF1 also abol-
ished detectable binding of the latter to Rama 27 fibroblasts
(figure 3d). Treatment of fixed Rama 27 cells with heparinaseswas similarly effective in reducing the binding of TMR-Halo-
FGF1 below the limit of detection (figure 3e). However,
digestion with chondroitinase ABC increased the level of fluor-
escence (figure 3f). The increase in binding of Halo-FGF1
observed after chondroitinase ABC treatment may indicate
that removal of chondroitin sulfate changed the structure
of ECM and somehow increased the number of available HS
binding sites for FGF1 (figure 3f). Collectively, these data
demonstrate that the detectable fluorescent Halo-FGF1, like
the Halo-FGF2, is bound to the HS of the pericellular matrix
of Rama 27 fibroblasts. Although FGF1 binds HS preferentially,
it also binds dermatan sulfate more weakly [29], but dermatan
sulfate binding sites are either not available or too weak in
Rama 27 pericellularmatrix, because chondroitinase ABC treat-
ment increased, rather than decreased binding. Interactions
with the FGFR are below the level of detection,which is consist-
ent with the relative numbers of binding sites corresponding
to HS and the FGFR established previously for FGF2 in these
cells [27,38].
(b)(a) (c)
(d ) (e) ( f )
Figure 3. Halo-FGF1 binding to Rama 27 fibroblasts. The binding specificity of Halo-FGF1 to fixed Rama 27 fibroblasts was tested by competing with unlabelled
FGF1 and heparin and by digestion with heparinase and chondroitinase ABC. (a) Cells were incubated with 2 nM TMR-Halo-FGF1 at 378C for 30 min. (b,c) 2 nM
TMR-Halo-FGF1 was added with (b) 8 mM unlabelled Halo-FGF1 or (c) 8 mM unlabelled FGF1. (d ) TMR-Halo-FGF1 (2 nM) in the presence of 4 mg ml21 heparin.
(e,f ) TMR-Halo-FGF1 binding to Rama 27 fibroblasts previously subjected to digestion with heparinase I, II and III, and chondroitinase ABC, respectively. The cor-
responding bright field images are presented in electronic supplementary material, figure S2. Size of the scale bar is 20 mm.
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Halo-FGF6 bound only slightly less than FGF2 to fixed Rama
27 fibroblasts, and again the fluorescence was not homo-
geneous (figure 4a). No binding of Halo-FGF6 was observed
on the fixed Rama 27 fibroblasts when TMR-Halo-FGF6 was
added with 4 mg ml21 heparin (figure 4b). Similar to FGF1
and FGF2, digestion ofHSbyheparinase decreased the binding
of TMR-Halo-FGF6 to undetectable levels (figure 4c), whereas
digestion of chondroitin sulfate and dermatan sulfate led to
an increase in Halo-FGF6 binding to the cells, as seen with
FGF1 (figure 4d). These results indicated that the detectable
Halo-FGF6 was bound to HS in the pericellular matrix of
Rama 27 fibroblasts. The number of these sites is similar to
those recognized by FGF2, but chondroitin sulfate (or derma-
tan sulfate) would appear to prevent directly or indirectly
some Halo-FGF6 binding to the HS in the pericellular matrix.3.2.4. Halo-FGF10
Halo-FGF10 only bound to some areas of the pericellular
matrix, whereas in other areas, virtually no binding was
detected (figure 4e). Thus, the binding of Halo-FGF10 to
Rama 27 fibroblasts was characterized by very substantial het-
erogeneities. The binding sites onRama27 fibroblasts for FGF10
were also blockedbyaddition of 4 mg m21 heparin,which effec-
tively prevented FGF10 binding to fixed Rama 27 fibroblasts
(figure 4f ). Digestion ofHSwith heparinase I, II and III reduced
the level of binding of Halo-FGF10 (figure 4g), but unlike
Halo-FGF1, Halo-FGF2 and Halo-FGF6, did not abolish it
(figures 2h, 3e and 4c). Moreover, digestion of chondroitin sul-
fate/dermatan sulfate with chondroitinase ABC also reduced
the amount of bound Halo-FGF10 (figure 4h). These results
indicated that Halo-FGF10 may bind to both HS andchondroitin sulfate in Rama 27 fibroblasts pericellular matrix.
Therefore, a double digestion (heparinase and chondroitinase)
was performed. When both sets of glycosaminoglycans were
digested, the level of bound Halo-FGF10 was nearly undetect-
able (figure 4i), demonstrating that FGF10 does indeed bind
to both chondroitin (dermatan) sulfate and HS.3.3. Comparison of binding of Halo-FGFs to Rama 27
cell pericellular matrix heparan sulfate
Quantification of the level of binding of theHalo-FGFs to Rama
27 cell pericellular matrix revealed some marked differences.
The level of binding was determined by calculating the aver-
aged fluorescence intensity of the highlighted cell area to
compare their binding capacities with the pericellular matrix.
There were more binding sites for Halo-FGF1 than the other
Halo-FGFs (figure 5a). Based on a Tukey t-test, the binding
capacities of Rama 27 pericellular matrix for Halo-FGF2 and
for Halo-FGF6 were also significantly different (p ¼ 0.005,
Tukey test) with Halo-FGF2 possessing more binding sites. In
terms of binding intensity, Halo-FGF6 and Halo-FGF10 did
not have significant difference ( p ¼ 0.08), but the distributions
of Halo-FGF10 and the other three Halo-FGFs were clearly not
the same (figure 5a). For example, Halo-FGF6wasmore evenly
distributed in pericellular matrix, with a level of heterogeneity
similar to that seen withHalo-FGF2, whereasHalo-FGF10 only
bound to specific areas of the pericellular matrix. In contrast,
Halo-FGF20 bound extremely weakly, if at all, and it was
consistently under the detection limit (figure 5a; electronic
supplementary material, figures S4a,b).
These results differ from those obtained upon affinity
chromatography of these FGFs to heparin [31]. The previous
work indicated that Halo-FGF2, Halo-FGF1 and Halo-FGF10
(b)(a) (c)
(h)(g) (i)
(d ) (e) ( f )
Figure 4. Binding specificity of Halo-FGF6 and Halo-FGF10 to Rama 27 fibroblasts. Halo-FGF6 and Halo-FGF10 were used to label fixed Rama 27 fibroblasts and
heparin, and the enzyme digested fibroblast pericellular matrix was used to determine their binding specificity. (a) Rama 27 fibroblasts were incubated with 2 nM
TMR-Halo-FGF6. (b) 2 nM TMR-Halo-FGF6 in the presence of 4 mg ml21 heparin. (c,d) 2 nM TMR-Halo-FGF6 binding to Rama 27 fibroblast pericellular matrix
digested with heparinase I, II and III, and chondroitinase ABC, respectively. (e) Rama 27 fibroblasts were incubated with 2 nM TMR-Halo-FGF10. ( f ) TMR-Halo-
FGF10 (2 nM) in the presence of 4 mg ml21 heparin. (g,h) TMR-Halo-FGF10 (2 nM) binding to Rama 27 fibroblasts pericellular matrix digested with heparinase
I, II and III, and chondroitinase ABC, respectively. (i) 2 nM Halo-FGF10 binding to the pericellular matrix digested by both heparinase I, II and III, and chondroitinase
ABC. The corresponding bright field images are presented in electronic supplementary material, figure S3. Size of the scale bar is 20 mm.
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was required to efficiently elute them from heparin-affinity
chromatography matrices. Both Halo-FGF6 and Halo-FGF20
could stably bind to heparin in 0.4 M NaCl. Though less
Halo-FGF20 was bound than Halo-FGF6, this was due to a
reduced capacity of the heparin affinity column for Halo-
FGF20 [31]. This is consistent with the recent analysis of the
structures in glycosaminoglycans recognized by FGFs, includ-
ing FGF20, which requires long (more than 12 saccharides)
sequences of sulfated saccharides for binding [30]. Such
sequences would be rare in HS, though they may be present
in HS of particular cells (e.g. syndecan-2 heparan suflate from
liver) [39]. The present data also highlight that binding to
heparin, which is far more sulfated than HS, does not reflect
the binding capacity of HS, which is both less sulfated and
more structurally diverse [1–3,40], which allows a far more
selective interaction with individual proteins [7,41]. Moreover,
the affinity of HS for a particular FGFmay not predict the level
of biding to the polysaccharide on the cell. Thus, the affinity of
FGF1 for HS purified from Rama 27 cells is at least an order ofmagnitude lower than that of FGF2 [37], yet Halo-FGF1 binds
to a greater extent than Halo-FGF2 (figure 5a).
The binding and competition data demonstrate that the
detectable binding of the four Halo-FGFs is to glycosaminogly-
cans in the pericellular matrix. In the presence of heparin, these
FGFswill interactwith their receptor tyrosine kinase [42]. Thus,
the absence of binding of Halo-FGF2 detected in the presence
of heparin is in agreement with previous work, which
showed that the number of HS-binding sites for FGF2 is several
orders of magnitude greater than the number of receptors [27].
A similar difference is therefore likely to exist for FGF1, FGF6
and FGF10, because binding was not detected in the presence
of heparin (figures 2g, 3d and 4b,f). Whereas Halo-FGF1,
Halo-FGF2 and Halo-FGF6 interacted only with HS, Halo-
FGF10 had a significant interaction with chondroitin sulfate
(and/or dermatan sulfate) species on Rama 27 fibroblasts
(figure 5b). FGF1 has previously been shown to interact with
dermatan sulfate, but not chondroitin sulfate, whereas FGF7,
which is in the same subfamily as FGF10, interacts weakly
with both chondroitin sulfate and dermatan sulfate [29].
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Figure 5. Quantification of binding of different Halo-FGFs to Rama 27 fibroblast pericellular matrix. (a) TMR-labelled Halo-FGF1, Halo-FGF2, Halo-FGF6, Halo-FGF10,
Halo-FGF20 and HaloTag (all 2 nM) were incubated with fixed Rama 27 fibroblasts, as described in figures 2a, 3a, 4a,e and electronic supplementary material, figure
S4a,b. The fluorescence in the highlighted cell area was averaged to quantify the level of binding of the FGF to Rama 27 pericellular matrix. Fluorescence intensities
on different cells in the same set of dish and different sets of dishes were acquired and are shown as a box plot. Each symbol corresponds to independent dishes of
cells measured on different days. (b) The binding intensities of Halo-FGF1, Halo-FGF2, Halo-FGF6 and Halo-FGF10 to Rama 27 fibroblasts pericellular matrix digested
with heparinase I, II and III, and with chondroitinase ABC were quantified and normalized to the values obtained with untreated matrix.
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shown to bind to chondroitin sulfate and dermatan sulfate
[30]. In the case of Halo-FGF1, either the interaction with der-
matan sulfate is too weak to be detectable or there is little
dermatan sulfate with appropriate binding structures in
Rama 27 cell pericellular matrix. In contrast, the interaction of
Halo-FGF10 with chondroitin sulfate and/or dermatan sulfate
on these cells is sufficiently strong to be detected (figure 5b).
The increase in binding observed with Halo-FGF1 and
Halo-FGF6 upon chondroitinase ABC treatment of cells
suggests that chondroitin sulfate may somehow mask HS
binding sites for these Halo-FGFs. Whether such masking
occurs directly or owing to bridging by endogenous proteins
that bind both chondroitin sulfate and HS is not known. It is
intriguing that the effect is not seen with Halo-FGF2, because
this is in the same subfamily as FGF1, and the major differ-
ence in binding selectivity between these FGFs is that FGF1
readily binds tracts of sulfated saccharides containing 6-O-sulfated glucosamine with one of N-sulfated glucosamine
or 2-O-sulfated iduronic acid, whereas FGF2 binds these
poorly [5,7,43]. With respect to desulfated structures, the
binding selectivity of FGF6 lies between that of FGF1 and
FGF2, because FGF6 has a preference for structures contain-
ing 2-O-sulfated iduronate, but it does bind structures
containing N-, and 6-O-sulfated glucosamine that lack sulfate
on iduronate [30]. Thus, the masking effect of chondroitin
sulfate on Halo-FGF1 and Halo-FGF6 binding to HS may
be related to their interactions with such structures in HS.
The binding of all the Halo-FGFs was observed to be het-
erogeneous. This indicates that the distribution of binding
sites for Halo-FGF1, Halo-FGF2 and Halo-FGF6 in HS and
for Halo-FGF10 in HS and chondroitin sulfate are not
evenly distributed across the pericellular matrix. This is con-
sistent with similar imaging of gold nanoparticle-labelled
FGF2 by photothermal heterodyne imaging (optical resol-
ution) and by transmission electron microscopy [27,44].
rsob.royalsocietypublishing.org
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observed clustering of FGF2 binding sites in HS of Rama 27
cell pericellular matrix may be a more general phenomenon,
because it is seen here with four FGFs from three different
subfamilies that possess different binding selectivity for HS
[29,30]. This suggests that the binding sites for these FGFs are
spatially organized in Rama 27 pericellular matrix, and this is
likely to extend to supramolecular length scales (distance equiv-
alent to several/many HS chains). Such organization would
arise from the interaction of HS and (for FGF10) chondroitin sul-
fate/dermatan sulfate chains with their endogenous binding
proteins,which forHShavebeen catalogued to at least 883 [4,45].en
Biol.6:1502773.4. Detection of FGF diffusion by fluorescence recovery
after photobleaching
The differences in the binding of Halo-FGF1, 2, 6, 10 and 20 to
Rama 27 pericellular matrix, relate, at least in part, to differ-
ences in the structures these FGFs bind in HS (and
chondroitin sulfate/dermatan sulfate for FGF10). It is estab-
lished in some cases that the interaction of proteins with
HS can control their movement in the extracellular space
[15,27,46–48]. Therefore, to determine if the differences in
HS binding may result in differences in movement in extra-
cellular matrix, we measured the diffusion of Halo-FGF1, 2,
6 and 10 in Rama 27 pericellular matrix by FRAP.
The FRAP experiments employed the same labelling proto-
col as the imagingones. Fixedcellswere againused,because this
allowed the measurement of the diffusion of each Halo-FGF in
pericellular matrix to bemadewithout any confounding effects
that might have arisen owing to the movement of cells or of
membrane. Paraformaldehyde reacts with primary amine
groups and will not affect the binding structures of the FGFs
used here, because these do not bind tracts of saccharides con-
taining unsubstituted glucosamine [30] and in any event, such
residues are rare in HS [49]. However, the fixative may cross-
link endogenous multivalent HS-binding proteins and the
core proteins of HS proteoglycans. This may then restrict move-
ment of HS chains and diffusion in the membrane of the HS
proteoglycan core proteins, both of which will restrict the free-
dom of the HS chains [27], though this effect may be less
pronounced on glycosyl–phosphatidylinositol-anchored glypi-
cans than transmembrane core proteins such as syndecans [50].
Another important feature of these experiments is that follow-
ing the binding of Halo-FGFs to HS in the pericellular matrix,
the cells were washed to remove unbound Halo-FGF. Trapping
of FGF2 on HS in the extracellular matrix has been well docu-
mented [14,15,27,51–54] and, given a suitable density of HS-
binding sites, is a general property of extracellular matrix
[15,20,48,55]. As for FGF2 [27], Halo-FGF1, Halo-FGF2 and
Halo-FGF6 bound to the pericellular matrix did not dissociate
appreciably into the bulk culture medium over 270 s (electronic
supplementary material, figure S5). Thus, because FRAP
measurements were made in 197 s, dissociation into the bulk
culture medium followed by re-association with HS in the peri-
cellularmatrix cannot contribute to the recoveryof fluorescence.
Instead, the recovery of fluorescence will be due to diffusion of
these Halo-FGFs within the pericellular matrix.
After the bleaching iterations, the selected area became
dark (figure 6a,b,e,f,i,j). Recovery of fluorescence then occurred
(figure 6c,d,g,h,k,l ). These data demonstrate that the Halo-FGFs
were able to diffuse between the bleached and surroundingareas of pericellular matrix in fixed Rama 27 cells. Thus,
while these Halo-FGFs were clearly trappedwithin the pericel-
lular matrix (electronic supplementary material, figure S5),
they were able to diffuse within it. Movement of nanoparti-
cle-labelled FGF2 has similarly been evidenced before by
photothermal imaging, tracking and raster image correlation
spectroscopy [27,44]. Earlier work also demonstrated that
FGF2 trapped on HS in extracellular matrix was mobile [15].
Thus, the present data demonstrate that the movement of pro-
teins bound to HS and trapped in extracellular matrix is likely
to be a more general phenomenon.3.5. Quantification of diffusion of Halo-FGF1, Halo-FGF2,
Halo-FGF6 and Halo-FGF10
The fluorescence intensity of the bleached area during recovery
was quantified as the normalized fluorescence (Materials and
methods). In the case of Halo-FGF1, recovery was partial
after 64 s and still not complete by 196 s (figure 6c,d; electronic
supplementary material, videos S7 and S8). The fluorescence
recovery curve shows that Halo-FGF1 fluorescence in the
bleached area recovered relatively slowly and by 196 s only
half the fluorescence was recovered (figure 7a). The decrease
of fluorescence intensity of the reference area was due to the
photobleaching by the imaging laser (electronic supplementary
material, figure S6a,b), because Halo-FGF1, Halo-FGF2 and
Halo-FGF6 could be trapped in the pericellular matrix for
more than 4.5 min (electronic supplementary material, figure
S5), as discussed above. The recovery of fluorescence was
greater for Halo-FGF2, although the recoverywas not complete
after 196 s (figure 6g,h; electronic supplementary material,
video S9). Quantification of the recovery of Halo-FGF2 fluor-
escence demonstrates that this is substantially faster than that
of Halo-FGF1 and the final level of fluorescence, 80%, was
higher (figure 7b). The fluorescence of Halo-FGF6 recovered
similar to that of Halo-FGF2 (figure 6k,l; electronic supple-
mentary material, video S10). The rate of fluorescence
recovery of Halo-FGF6 was somewhat faster than Halo-FGF2,
though the level of recovery attained after 196 s was similar
(figure 7c,e). The weaker photobleaching for Halo-FGF2
might suggest that the bleached Halo-FGF2 and Halo-FGF6
during imaging could be quickly exchanged into the surround-
ing areas that were not imaged (electronic supplementary
material, figure S6c,d).
The fluorescence recovery curves (figure 7a–c) allowed
the calculation of the half recovery time, which is directly
related to the movement of molecules in the FRAP experiments
and the relative proportions ofmobile and immobileHalo-FGF.
The half recovery times demonstrated that Halo-FGF1 diffused
more slowly in the pericellular matrix of Rama 27 fibroblasts
than Halo-FGF2 or Halo-FGF6 (figure 8a). Moreover, Halo-
FGF6 had the shortest half recovery time (16 s), which was
significantly ( p ¼ 0.0008, Tukey test) faster than that of
Halo-FGF2 (22 s) and of Halo-FGF1 (49 s). Thus, the difference
of final level of recovered fluorescence and the initial fluor-
escence is indicative of the fraction of immobile Halo-FGFs.
Only 52% of Halo-FGF1 was mobile, whereas 81% of
Halo-FGF2 and 82% of Halo-FGF6 were mobile (figure 8b).
Previous work demonstrates that FGF2 that appears immobile
at the resolution of a confocal microscope will in fact be under-
going confined motion, diameter approximately 100 nm [27].
Like Halo-FGF2, Halo-FGF1 and Halo-FGF6 are also bound
(a)
(e)
(i)
(b)
(f)
(j)
(c)
(g)
(k)
(d)
(h)
(l)
before bleaching bleaching recovery (64 s) recovery (196 s)
Halo-FGF1
Halo-FGF2
Halo-FGF6
Figure 6. FRAP of Halo-FGF1, Halo-FGF2 and Halo-FGF6 in Rama 27 fibroblast pericellular matrix. Fixed Rama 27 fibroblasts were used to provide a pericellular
matrix that could be probed with Halo-FGF1, Halo-FGF2 and Halo-FGF6. A 5 mm radius disc area on the cell was bleached by full power laser to measure the
recovery of the fluorescence in the bleached area. (a,e,i) TMR-Halo-FGF1, -FGF2 and -FGF6 labelled cells before bleaching. (b,f,j) Same areas as (a,e,i), but following
the bleaching of a 5 mm radius disc. (c,g,k) The partial recovery of fluorescence in the bleached area 64 s after bleaching. (d,h,l) Images acquired when the bleached
area had recovered to a stable level (196 s). Size of the scale bar is 5 mm.
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ences in the distribution and number of their available binding
sites on HS chains, it seems reasonable to suggest that the
immobile fraction of Halo-FGF1 and Halo-FGF6 are also
undergoing similar confined motion.
Analysis of the movement of FGF2 at the single molecule
level revealed that it undergoes different types of diffusive
motion over different length scales. To see if some insight
could be gained from the present average measurements of
Halo-FGF diffusion into the types of movements the FGFs
underwent, the fluorescence of the bleached area and sur-
rounding unbleached area were determined as a series of
radial profiles, diameter 14 mm. These analyses are presented
as the radial profile at selected times: before bleaching, after
bleaching, at the time corresponding to half recovery of the
final fluorescence and at final recovery. The results show that
the radial profile after bleaching (figure 7d–f, blue lines) is
‘U’ shaped, but, as the bleached area recovered, the profile
(figure 7d–f, pink lines) it became more ‘V’ shaped. Moreover,
for Halo-FGF1, as the recovery profile of the bleached area
(2.5 mm radius) increased, there was a small decrease in fluor-
escence in the surrounding unbleached area (figure 7d, pink
line and green line). Together, this suggests that the majority
of the movement of the Halo-FGFs at these time scales is over
1 mm or less, corresponding to the confined and simple diffu-
sive motion observed previously with FGF2, and that FGF1
may undergo comparatively less fast and directed diffusion
[27]. In contrast, the half recovery profiles of Halo-FGF2 and
Halo-FGF6 (figure 7e,f, pink lines) were more ‘U’ shaped, and
the fluorescence of the surrounding unbleached areas wasnot much affected during recovery (figure 7d, pink line). More-
over, the final recovery profiles of Halo-FGF2 and Halo-FGF6
were close to that seen before bleaching (figure 7e,f, green
lines). These data are consistent with the previous demon-
stration that FGF2 can undergo fast and directed diffusion in
addition to confined and simple diffusive motion, and it
would appear that Halo-FGF6 may undergo similar types
of movement.
Because the distribution of Halo-FGF10 in Rama 27 fibro-
blast pericellular matrix was very heterogeneous, FRAP
experiments were conducted to determine the diffusion of
Halo-FGF10 in both areas of high (figure 9a–c) and lower
binding (figure 9d–f). As for Halo-FGF1, Halo-FGF2 and
alo-FGF6, a small area of the cells was bleached, and the
fluorescence recovery was measured over the following 196 s
(figure 9a–c,d–f). Compared with the image acqui-
red immediately after bleaching, there was no obvious
recovery of fluorescence after 196 s (figure 9b,c,e,f). The
averaged fluorescence recovery curve demonstrates that the
TMR-Halo-FGF10 in the bleaching area did not exchange
appreciably with the TMR-Halo-FGF10 outside the bleached
area (figure 9g). These data suggest that FGF10 does not dis-
sociate readily from the HS, chondroitin sulfate and dermatan
sulfate chains it is bound to. Interestingly, the thermal shift
assay used to identify its selectivity for sulfation patterns with
a library ofmodified heparins shows that rather than equilibrat-
ing between bound and unbound forms, FGF10 appears to
partition into two populations, FGF10 and FGF10 bound to
heparin [30]. This is consistent with a very slow dissociation
of FGF10 from heparin, because faster dissociation would
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Figure 7. Fluorescence recovery curves and recovery radial profiles of Halo-FGF1, Halo-FGF2 and Halo-FGF6 in Rama 27 fibroblast pericellular matrix. The fluorescence
intensity of the bleaching area was analysed, as described in materials and methods, to identify the different recovery patterns. The radial profile of the bleached
area was extracted from the imaging data to reflect how the FGFs exchanged between the bleached area and the surrounding non-bleached pericellular matrix.
(a,b,c) The normalized fluorescence intensities of (a) Halo-FGF1, (b) Halo-FGF2 and (c) Halo-FGF6 in the bleached area were plotted against time (average of 10
measurements for Halo-FGF1, 17 measurements for Halo-FGF2 and 28 measurements for Halo-FGF6). (d,e,f ) The radial profiles of the bleached area before bleaching,
immediately after bleaching, when fluorescence had reached half the final recovery value and at final recovery were extracted from the imaging data. Multiple
repeats were applied to acquire the standard deviation. The mean of radial profiles for each FGF was plotted with standard deviation area against the distance
to the centre of the bleached disc area (18 measurements for Halo-FGF1, 23 for Halo-FGF2 and 17 for Halo-FGF6). m is the mean value of multiple fluorescence
intensity curves for each FGF; s is the standard difference; ‘before’ is before bleaching; ‘after’ is the image immediately after bleaching; ‘half ’ is the time when the
fluorescence was recovered to half of the final recovery level; ‘final’ is the time for the last measurement.
rsob.royalsocietypublishing.org
Open
Biol.6:150277
11
 on March 23, 2016http://rsob.royalsocietypublishing.org/Downloaded from enable exchange of FGF10 molecules on the heparin, and so an
averaging of the measured thermal stability of bound and
unbound species. Work in two development models where
FGF10 has a role in epithelial morphogenesis, in lung and sali-
vary gland morphogenesis, also indicate that FGF10 bound to
glycosaminoglycans does not readily dissociate and thatFGF10 diffusion requires either suboptimal binding structures
or the action of heparanase [21,56].
The substantial differences in diffusion observed between
Halo-FGF1, Halo-FGF2 and Halo-FGF6 may be a consequence
of differences in the number and spatial organization of their
respective binding sites on HS chains. Alternatively, the
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Figure 8. Quantification of moving speed and mobile/immobile fractions of Halo-FGF1, Halo-FGF2 and Halo-FGF6 on Rama 27 fibroblasts. The half recovery time and
final recovery level were extracted from each fluorescence recovery curve, as described in materials and methods. (a) The half recovery times for Halo-FGF1, Halo-
FGF2 and Halo-FGF6 were plotted to compare their diffusion speeds in the pericellular matrix. Each half recovery was extracted from one FRAP experiment, which
shows the time it took to recover to half of the final fluorescence intensity in each fluorescence recovery curve. (b) Normalized final recovery levels of the three FGFs
were used to determine the ratio of mobile and immobile FGF in the pericellular matrix. The final recovery level shows the mobile fraction, and the immobile
fraction is its difference from 100%. Each symbol corresponds to independent dishes of cells measured on different days.
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mobility, owing to crowding and a consequent lower avail-
ability of free binding sites. To distinguish between these
possibilities a lower concentration of Halo-FGF1 was used to
measure its diffusion.
3.6. Effect of changing the concentration of Halo-FGF1
The level of bound TMR-Halo-FGF1 was changed by halving
the concentration of Halo-FGF1 added to fixed Rama 27 cells,
which reduced the fluorescence intensity to levels similar to
that observed with 2 nM TMR-Halo-FGF2 (figure 10a). How-
ever, at the lower level of binding of Halo-FGF1, the recovery
of fluorescence following bleaching was similar to that
observed with 2 nM Halo-FGF1. The half recovery time for
1 nM Halo-FGF1 was 45 s, and only 50% of the fluorescence
was recovered. Consequently, reducing the amount of Halo-
FGF1 bound to the HS in pericellular matrix by a factor of
2 had no strong effect on the diffusion speed of the Halo-
FGF1 or on the relative proportions that were mobile andimmobile (figure 10b,c). These results indicate that the
slower diffusion observed with 2 nM Halo-FGF1 is unlikely
to be due to the larger amount of Halo-FGF1 bound to HS
in the pericellular matrix. Instead, the slower diffusion of
Halo-FGF1 is more likely to be due to differences in the
number and spatial organization of these binding sites, and
the rate of association and disassociation of the FGF1 from
them. Thus, the diffusion measurements suggest Halo-FGF1
is less mobile in pericellular matrix than FGF2 or FGF6 and
it moves in smaller steps. If there was a focal source of
FGFs, then FGF1 would form shorter and steeper gradients
than FGF2 and FGF6 in Rama 27 fibroblast matrix.3.7. Binding and movement of fibroblast growth factors
in extracellular matrix
The expansion of the FGF family is associated with an increase
in the complexity of multicellular organisms, highlighting its
importance in mediating cell communication in development
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Figure 9. Diffusion of Halo-FGF10 in Rama 27 fibroblast pericellular matrix. Fixed Rama 27 fibroblasts were used to provide a pericellular matrix for Halo-FGF10
binding. A 5 mm radius disc area on the cell was bleached by full power laser to measure the recovery of the fluorescence in the bleached area. The fluorescence
intensity of the bleached area was extracted to detect the diffusion of TMR-Halo-FGF10 in the pericellular matrix. (a,d) TMR-Halo-FGF10 labelled cells (two areas
with different binding intensities) before bleaching. (b,e) Same areas as (a,d), but following the bleaching of a 5 mm radius disc. (c,f ) The partial recovery of
fluorescence in the bleached area 196 s after bleaching. (g) The normalized fluorescence intensities of Halo-FGF10 in the bleached area were plotted against
time (average of 10 measurements). Size of the scale bar is 5 mm.
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related in amino acid sequence and in function than FGFs in
different subfamilies. The functional relations are evidenced,
for example, by the selectivity of FGFs in different subfamilies
for isoforms of the FGFR [42,60], for the patterns of sulfated
sugars they bind in HS, and for the number and location of
HS binding sites on the FGF [29,30,61]. Previous work with
FGF2 demonstrated that its diffusion in pericellular matrix of
Rama 27 fibroblasts was controlled by the spatial organization
of its HS-binding sites [27]. This raises an important question:
whether the diffusion of other HS-binding effectors, with
different selectivity for patterns of sulfated sugars, also possess
heterogeneous networks of binding sites that control their dif-
fusion. To tackle this question, we have used five FGFs from
four different subfamilies, with well-characterized HS-binding
properties. This allows the effects of subtle differences between
members of the same subfamily (FGF1 subfamily: FGF1 and
FGF2) and more substantial differences between members of
different subfamilies (FGF6 is in the FGF4 subfamily, FGF10in the FGF7 subfamily and FGF20 in the FGF9 subfamily) to
be measured.
There are differences between the diffusion of FGFs occur-
ring in the experiments described here and in vivo. First, the
Halo-FGF is bound to pericellular matrix and any unbound
ligand is removed by washing. Thus, unlike in vivo, there is
no source of diffusing ligand. Second, because the cells are
fixed, receptor-mediated endocytosis cannot occur, so there is
no sink to remove ligand. Therefore, the binding experiments
(figures 2–4) provide a snapshot of the distribution of binding
sites on glycosaminoglycans in pericellular matrix. The FRAP
experiments measure the movement of the FGF owing to its
dissociation and re-association to sites on glycosaminoglycans,
without any effects of concentration gradients or cell biochem-
istry (membrane protein movement, membrane flow and cell
movement).
There are a large number of binding sites for FGFs and
otherHS-binding proteins on the polysaccharide in pericellular
matrix; for FGF2 in Rama 27 fibroblasts these amount to 3  106
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Figure 10. Effect of concentration of Halo-FGF1 and of Halo-FGF2 on their binding and diffusion in Rama 27 fibroblast pericellular matrix. TMR-Halo-FGF1 (1 nM)
was used to label fixed Rama 27 fibroblasts to identify any dependence of their level of binding and their diffusion on concentration. The FRAP experiments with
TMR-Halo-FGF1 (2 nM) and TMR-Halo-FGF2 (2 nM) were carried out at the same time and are shown in figures 7 and 8. Six FRAP experiments are included for each
sample. (a) Binding intensities of Halo-FGF1 (1 and 2 nM) and Halo-FGF2 (2 nM) at the areas for FRAP measurements. (b) The moving speed (half recovery time) of
different concentration of Halo-FGF1 and Halo-FGF2 in the matrix. (c) The mobile/immobile fraction (Final recovery level) of different concentration of Halo-FGF1 and
Halo-FGF2 in fixed Rama 27 fibroblasts pericellular matrix.
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different structures in HS and, perhaps unsurprisingly, their
level of binding differed considerably; FGF1 bound to the
greatest extent, whereas the binding of FGF20 was undetect-
able, because it was within the threshold of background
fluorescence (figures 2–4; electronic supplementary material,
figure S4). In all cases, the distribution of the FGFs was hetero-
geneous (figures 2–4), indicating that their binding sites are not
evenly distributed in pericellular matrix. This has been shown
previously for FGF2 over length scales ranging from 10 nm to
several micrometres in the same cells [27,44]. The clustering
of HS proteoglycans in lipid rafts would be one mechanism
that could contribute to the heterogeneous distribution of
HS-binding sites [62,63]. Other mechanisms may operate in
parallel. For example, interactions of transmembrane proteo-
glycans (e.g. syndecans [64]) with the cytoskeleton through
their cytoplasmic domains may lead to their localization to
particular membrane microdomains.
The present data demonstrate that the heterogeneous
distribution of binding sites observed previously with nano-
particle-labelled FGF2 [27,44] and in experiments with
radiolabelled FGF2 [65] is likely to be a more generalphenomenon, because it was observed here also with FGF1,
FGF6 and FGF10. One interpretation is that the HS chains pos-
sessing binding sites for a particular protein (FGFs in the
present case) are at least in part differently localized in pericel-
lular matrix, through, for example, the various clustering
above-discussed mechanisms. However, this interpretation is
likely to be too simplistic. For HS, there are 883 extracellular
proteins that bind it in the human proteome [4,45]. Thus, the
subset of the HS-binding proteins expressed by Rama 27 fibro-
blasts will have a substantial portion of their binding sites
engagedwithHS. Consequently, theHS-binding sites available
to a particular FGF (3  106 for FGF2 [27]) are likely to be
less than the total possible binding sites. Moreover, these
HS-binding proteins also have very extensive networks of
protein–protein interactions [4,45], which will influence their
protein–polysaccharide interactions. One consequence of this
multiplicity of interactions is that there are many free binding
sites for exogenously added proteins on HS (figures 2–4) and
there are many free binding sites on endogenous HS-binding
proteins for exogenously added polysaccharide [66]. Thus,
pericellular matrix is not at equilibrium and the ingress of an
HS-binding protein may perturb a wide range of interactions.
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three-dimensional structure of HS chains. For example, a
number of HS-binding proteins are multivalent, that is they
have more than one binding site for the polysaccharide
[28–30,61,67–70]. A recent biophysical analysis of brushes of
HS chains demonstrated that some HS-binding cytokines and
growth factors with multiple binding sites are able to cross-
link the chains [28]. Because HS-binding matrix proteins such
as collagens and fibronectin have multiple binding sites for
the polysaccharide, it seems reasonable that they too will in
some instances cross-link HS chains. Thus, the HS chains in
pericellularmatrix are likely to be engaged in large-scale supra-
molecular networks, which may ultimately be responsible for
the heterogeneous distribution of binding sites and through
which the Halo-FGFs diffuse.
The FRAP data for the four FGFs with detectable binding
show that they move differently in Rama 27 fibroblast pericel-
lular matrix (figures 7–10). In the case of FGF1 and FGF2, the
slower movement of the former may be explained by its
larger number of binding sites. Within the FGF1 subfamily,
FGF1 binds to any disulfated saccharide structure of degree
of polymerization (dp) 4 or longer, whereas FGF2 requires
N-sulfate and 2-O-sulfated groups [5,7,43,71]. Thus, even
taking into account occupation of some sites by endogenous
proteins, the greater promiscuity of FGF1 is likely to explain
why Halo-FGF1 binds Rama 27 pericellular matrix to a
greater extent than Halo-FGF2. The larger number of sites
in HS that FGF1 can bind may also underlie its more
restricted mobility; a greater density of binding sites would
reduce the distance the protein can travel in a given time,
because the likelihood of rebinding will be greater. Indeed,
binding site density and clustering have been shown to pre-
vent effective dissociation of HS-binding proteins such as
FGF2 from pericellular matrix and are likely to alter the
distance a protein can travel within pericellular matrix
before re-binding [15]. The differences in movement of the
other FGFs would then similarly reflect their selectivity
for binding structures in HS and how the available binding
structures are presented. In the extreme, as seen with
FGF10, the FGF does not diffuse appreciably over the time
of the FRAP measurement. In such instances, the movement
of the HS-binding protein would require additional mechan-
isms. This could be provided by heparanase, an extracellular
b glucuronidase, which cleaves HS chains in their transition
domains. This would release cargoes of S-domains and
bound protein, as shown for FGF2 in a skin wound healing
model [72]. Indeed, heparanase has been shown to be impor-
tant for the stimulation of ductal morphogenesis by FGF10 in
salivary gland [56].4. Conclusion
The selectivity of FGFs for different binding structures in gly-
cosaminoglycans provides a means to probe the distribution
of these binding sites in Rama 27 cell pericellular matrix andto determine the effect this has on the diffusion of the FGFs.
The results show that protein-binding sites in HS (and chon-
droitin sulfate/dermatan sulfate for FGF10) of pericellular
matrix are not homogeneously distributed. A number of
different mechanisms are likely to regulate the distribution
of these binding sites, including the biosynthesis of the HS
chains, the localization of core proteins in membrane micro-
domains and the interactions of the polysaccharide chains
with endogenous HS-binding proteins. The high multiplicity
of interactions, both between proteins and polysaccharide
and between the polysaccharide-binding proteins themselves
[4] (reviewed in [1,2]), is likely to produce a dynamic network
of interlinked molecules. This would then be responsible for the
long-range (supramolecular) structure of the pericellular matrix,
which determines its spatial binding capabilities for individual
proteins. Such a structure would be sensitive to perturbations,
suchas the ingress of anHS-bindingprotein fromaneighbouring
cell (in the sameordifferent tissue compartment), and can control
the diffusion of such effector proteins. Supramolecular structure
in extracellular matrix has been shown in cartilage [73], where
there are also definitive structural and functional differences
between the pericellularmatrix of chondrocytes, and the territor-
ial and inter-territorial matrices that are more distant from the
cells. Thus, although extracellular matrix in cartilage is special-
ized, in other tissues, an analogous situation may exist, where
pericellular, extracellular and basement membrane matrices
may exhibit different types of supramolecular structure and
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